Clinical trial
A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation
NCT01134484 is registered in ClinicalTrials.gov with Michele Cavo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation
- Lead sponsor
- Michele Cavo
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- May 31, 2006
- Completion date
- December 31, 2015
- Enrollment
- 480 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.